semaglutide for Stroke Rehabilitation: Mechanisms, Evidence, and Dosing Guide

Medically reviewed by Dr. James Whitfield, DO, FACOI

## Semaglutide for Stroke Rehabilitation: Mechanisms, Evidence, and Dosing Guide Stroke remains a leading cause of long-term disability worldwide. Wh...

Semaglutide for Stroke Rehabilitation: Mechanisms, Evidence, and Dosing Guide

Stroke remains a leading cause of long-term disability worldwide, imposing significant burdens on individuals, families, and healthcare systems. While rehabilitation therapies are the cornerstone of recovery, there is a growing interest in pharmacological agents that can enhance the brain's ability to repair and reorganize itself. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising candidate in this regard, primarily due to its established metabolic benefits and increasingly recognized neuroprotective properties.

Mechanisms of Action in Stroke Recovery

Semaglutide's potential benefits in stroke rehabilitation are believed to stem from its multifaceted effects on the brain, extending beyond its primary role in glucose homeostasis. These mechanisms are crucial for mitigating ischemic damage and promoting neural repair.

Neuroprotection: Semaglutide has been shown to protect neurons from damage and death in various in vitro and in vivo models of stroke. This is thought to be mediated by its anti-inflammatory, anti-apoptotic, and anti-oxidative properties. GLP-1 receptors are expressed in various brain regions, including the hippocampus, cortex, and brainstem, allowing semaglutide to exert direct effects. It can reduce oxidative stress by enhancing antioxidant enzyme activity and decreasing reactive oxygen species production, thereby preserving neuronal integrity [1, 4]. Furthermore, semaglutide modulates inflammatory pathways, reducing the release of pro-inflammatory cytokines such as TNF-α and IL-1β, which are significant contributors to secondary brain injury post-stroke [1].

Neurogenesis: Some studies suggest that semaglutide may promote the birth of new neurons (neurogenesis) in the hippocampus, a brain region crucial for learning and memory. This effect is particularly relevant in the subgranular zone of the dentate gyrus, a known neurogenic niche. By stimulating neural stem cell proliferation and differentiation, semaglutide could contribute to functional recovery by replenishing lost neurons and integrating new ones into existing neural circuits [5].

Synaptic Plasticity: Semaglutide may enhance synaptic plasticity, the ability of synapses to strengthen or weaken over time, which is essential for learning and recovery of function after a stroke. This involves modulating long-term potentiation (LTP) and long-term depression (LTD), key cellular mechanisms underlying learning and memory. Improved synaptic function can facilitate the reorganization of neural networks, allowing undamaged brain regions to take over functions previously performed by damaged areas [6].

Improved Cerebral Blood Flow: Beyond direct neuronal effects, GLP-1 receptor agonists can also improve cerebral blood flow. This is achieved through vasodilation of cerebral vessels and potentially by reducing endothelial dysfunction, ensuring better oxygen and nutrient supply to ischemic penumbra and recovering brain tissue [7].

  • Mitochondrial Function Enhancement: Semaglutide has been implicated in improving mitochondrial function, which is often compromised in ischemic conditions. By enhancing mitochondrial biogenesis and reducing mitochondrial dysfunction, semaglutide can support cellular energy production and reduce the release of pro-apoptotic factors, thus contributing to neuronal survival [8].

    • Clinical Evidence for Semaglutide in Stroke Rehabilitation

    While most of the evidence for semaglutide in stroke comes from preclinical studies, the results are encouraging and lay the groundwork for human trials. Several large cardiovascular outcomes trials (CVOTs) for GLP-1 receptor agonists, including semaglutide, have shown reductions in major adverse cardiovascular events (MACE), which include non-fatal stroke, suggesting a broader protective effect.

    | Study | Model / Population | Key Findings